| 1 |
34031800 | Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study. | 2022 Jan |
1 |
| 2 |
34597253 | Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease. | 2022 Feb |
1 |
| 3 |
34823038 | Long-term changes in short-interval intracortical facilitation modulate motor cortex plasticity and L-dopa-induced dyskinesia in Parkinson's disease. | 2022 Jan-Feb |
1 |
| 4 |
34990933 | Indoles and 1-(3-(benzyloxy)benzyl)piperazines: Reversible and selective monoamine oxidase B inhibitors identified by screening an in-house compound library. | 2022 Feb |
1 |
| 5 |
35001806 | Safinamide protects against amyloid β (Aβ)-induced oxidative stress and cellular senescence in M17 neuronal cells. | 2022 Jan |
2 |
| 6 |
35107654 | A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. | 2022 Jun |
1 |
| 7 |
35190544 | Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus. | 2022 Feb 21 |
1 |
| 8 |
35596745 | Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation. | 2022 May 21 |
2 |
| 9 |
32681474 | The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study. | 2021 Jun |
2 |
| 10 |
33068177 | Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. | 2021 Feb |
1 |
| 11 |
33387637 | Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies. | 2021 Mar |
1 |
| 12 |
34142645 | Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study. | 2021 Nov |
1 |
| 13 |
34162132 | Safinamide prevents lipopolysaccharide (LPS)-induced inflammation in macrophages by suppressing TLR4/NF-κB signaling. | 2021 Jul |
2 |
| 14 |
34390968 | Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies. | 2021 Oct |
3 |
| 15 |
34784871 | How to optimize the effectiveness and safety of Parkinson's disease therapy? - a systematic review of drugs interactions with food and dietary supplements. | 2021 Nov 16 |
1 |
| 16 |
34970960 | The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update. | 2021 Dec 31 |
1 |
| 17 |
32446176 | Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study. | 2020 Jun |
2 |
| 18 |
32612042 | [Safinamide Mesilate (Equfina® TABLETS 50 mg): preclinical and clinical pharmacodynamics, efficacy, and safety]. | 2020 |
1 |
| 19 |
32648512 | Safinamide in the treatment of Parkinson's disease. | 2020 Aug |
1 |
| 20 |
32673884 | Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study. | 2020 Sep 15 |
1 |
| 21 |
32682215 | Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1α signaling pathway and mitochondrial uncoupling protein -2(UCP-2). | 2020 Oct |
4 |
| 22 |
30160213 | Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. | 2019 |
3 |
| 23 |
30919054 | Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. | 2019 Jun |
2 |
| 24 |
29339106 | Safinamide: a new hope for Parkinson's disease? | 2018 Mar |
2 |
| 25 |
29464559 | Monoamine Oxidases. | 2018 |
1 |
| 26 |
29542008 | Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain. | 2018 Apr |
1 |
| 27 |
29760163 | ▼ Safinamide for Parkinson's disease. | 2018 May |
3 |
| 28 |
30142650 | [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. | 2018 Oct |
2 |
| 29 |
30341696 | Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. | 2018 Nov |
1 |
| 30 |
27665574 | Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. | 2017 Mar |
1 |
| 31 |
27855360 | Benzyloxynitrostyrene analogues - A novel class of selective and highly potent inhibitors of monoamine oxidase B. | 2017 Jan 5 |
1 |
| 32 |
28110399 | Safinamide: A Review in Parkinson's Disease. | 2017 Feb |
2 |
| 33 |
28537214 | Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease. | 2017 Jun |
1 |
| 34 |
28682929 | Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease. | 2017 Sep/Oct |
2 |
| 35 |
28777756 | Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease. | 2017 |
3 |
| 36 |
29018297 | Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson's Disease. | 2017 Oct |
4 |
| 37 |
29130466 | [Safinamide from daily clinical practice: first clinical steps]. | 2017 Nov 16 |
1 |
| 38 |
26849427 | The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. | 2016 |
1 |
| 39 |
26917951 | Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. | 2016 |
1 |
| 40 |
27536120 | Emerging approaches in Parkinson's disease - adjunctive role of safinamide. | 2016 |
1 |
| 41 |
27803666 | Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. | 2016 |
2 |
| 42 |
26164425 | Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. | 2015 Jun |
1 |
| 43 |
26293004 | New treatments for levodopa-induced motor complications. | 2015 Sep 15 |
1 |
| 44 |
26744740 | Safinamide for symptoms of Parkinson's disease. | 2015 Nov |
1 |
| 45 |
24950010 | Treatment of early Parkinson's disease. | 2014 Aug |
1 |
| 46 |
25342080 | Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease. | 2014 Dec |
1 |
| 47 |
23360954 | Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. | 2013 Apr |
1 |
| 48 |
24053341 | Current status of safinamide for the drug portfolio of Parkinson's disease therapy. | 2013 Sep |
1 |
| 49 |
22948897 | The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. | 2012 Oct |
1 |
| 50 |
27186120 | Investigational agents in the treatment of Parkinson's disease: focus on safinamide. | 2012 |
1 |